Zinc Gluconate for Liver Protection

Mechanisms of Liver Protection

• Zinc gluconate induces enterocyte metallothionein, a cysteine-rich protein that binds copper and prevents its absorption from the gastrointestinal tract, in patients with liver disease 2, 3
• Zinc induces hepatocellular metallothionein, which binds excess toxic copper in the liver, preventing hepatocellular injury, as recommended by the American Association for the Study of Liver Diseases 1, 2

Clinical Evidence for Liver Protection

• In Wilson's disease, zinc treatment can generate a negative balance for copper and thereby remove stored copper from the liver, according to the European Association for the Study of the Liver 3, 4

Dosing and Administration

• The recommended dose is 150 mg elemental zinc/day, administered in three divided doses, 30 minutes before meals, as suggested by the American Gastroenterological Association 2, 3
• The zinc salt used does not make a significant difference in efficacy but may affect tolerability, as noted by the National Institute of Diabetes and Digestive and Kidney Diseases 2, 5

Limitations and Cautions

• Zinc is probably less effective than chelating agents in the treatment of established liver disease, particularly Wilson's disease, as stated by the American College of Gastroenterology 2, 7
• Exclusive monotherapy with zinc in symptomatic Wilson's liver disease is controversial and not recommended, according to the American Association for the Study of Liver Diseases 2, 8

Monitoring Treatment

• For patients with Wilson's disease, 24-hour urinary excretion of copper should be less than 75 μg per 24 hours on stable treatment, as recommended by the European Association for the Study of the Liver 6, 8

Comparative Effectiveness

• Zinc appears to be equally effective as D-penicillamine but better tolerated in some patients with Wilson's disease, as noted by the National Institute of Neurological Disorders and Stroke 6, 3
• For asymptomatic or presymptomatic patients with Wilson's disease, zinc may be used as first-line therapy, according to the American Association for the Study of Liver Diseases 6, 8